Technology
Health
Biotechnology

Insmed

$28.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.96 (-3.29%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Insmed and other stocks, options, ETFs, and crypto commission-free!

About

Insmed, Inc. operates as a biopharmaceutical company. It focus developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. Read More The firm develops and commercialization of ARIKAYCE or liposomal amikacin for inhalation for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Employees
373
Headquarters
Bridgewater, New Jersey
Founded
1988
Market Cap
2.18B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
910.90K
High Today
$29.00
Low Today
$28.21
Open Price
$28.86
Volume
322.37K
52 Week High
$31.58
52 Week Low
$11.31

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
US
North America

News

MarketBeatMar 7

Stock Price, News, & Analysis for Insmed

News stories about INSM stock have been trending somewhat positive on Thursday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insmed earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 1...

26
Seeking AlphaFeb 22

Insmed, Inc. (INSM) CEO William Lewis on Q4 2018 Results - Earnings Call Transcript

Insmed, Inc. (NASDAQ:INSM) Q4 2018 Results Earnings Conference Call February 22, 2019 8:30 AM ET Company Participants Blaine Davis - Vice President and Head of Investor Relations William Lewis - President and Chief Executive Officer Roger Adsett - Chief Commercial Officer Paolo Tombesi - Chief Financial Officer Conference Call Participants Ishmael Asante - Morgan Stanley Adam Walsh - Stifel Nicolaus Dana Flanders - Goldman Sachs Ritu Baral - Cowen and Company Joshua Schimmer - Evercore ISI Josep...

67
Yahoo FinanceFeb 22

Insmed: 4Q Earnings Snapshot

BRIDGEWATER, N.J. (AP) _ Insmed Inc. (INSM) on Friday reported a loss of $91.6 million in its fourth quarter. On a per-share basis, the Bridgewater, New Jersey-based company said it had a loss of $1.19. Losses, adjusted for amortization costs, were $1.17 per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.11 per share. The biopharmaceutical developing inhaled treatments for patients battling rare l...

4

Earnings

-$1.19
-$1.00
-$0.82
-$0.63
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.